SELLAS Life Sciences Group Inc. (SLS)
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SLS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.78B
- EPS (TTM)
- -$0.20
- Dividend yield
- None
- 52-week range
- 1.39 – 24.89
- Day range
- 13.39 – 15.19
- Volume / Avg
- 15.37M / 9.64M
- Beta
- —
- Shares outstanding
- 203.86M
52-week range
SLS stock today
SELLAS Life Sciences Group (SLS) closed at $13.66 on Nov 20, down 8.08% (-$1.20), versus the S&P 500's 3.70% decline. At this level, SLS sits in the middle of its 52-week range of $1.39 to $24.89: 45.1% below the high, set on Nov 17, 2026 and 882.7% above the low. SLS is up 262.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 792.8%.
SELLAS Life Sciences Group has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About SELLAS Life Sciences Group
Company profileSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Angelos M. Stergiou M.D., ScD h.c.
- Headquarters
- New York, NY
- Employees
- 13
- Website
- sellaslifesciences.com
Financial highlights
Full financialsSELLAS Life Sciences Group reported a net loss of $26.9 million, compared with a loss of $30.9 million a year earlier. Diluted earnings per share came in at -$0.25.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.00M | $7.60M |
| Growth | — | — | -100.00% | -86.84% | +300.00% |
| Net income | $-26.86M | $-30.88M | $-37.34M | $-41.30M | $-20.70M |
| EPS (diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$32.50+137.92%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.05 vs —
SLS news
All SLS news- SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Weekly Buzz: SNY, REGN Score Approvals; MIST Cuts Costs; ABBV, LLY, JNJ Strike DealsNasdaqABBV, BIIB, BMY, ENLV
- SELLAS Life Sciences Group, Inc. Prices $150.0 Million Public Offering of Common StockNasdaq
- SELLAS Life Sciences prices $150M public offering of common stockSeeking Alpha
- SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public OfferingGlobeNewswire
- SELLAS Life Sciences Mengumumkan Data Positif Kajian Pivotal Fasa 3 REGAL yang Menunjukkan bahawa Vaksin Kanser Imunoterapeutik Galinpepimut-S (GPS) Meningkatkan Kelangsungan Hidup Keseluruhan secara Signifikan dari Segi Statistik dan Bermakna dari Segi Klinikal dalam Kalangan Pesakit Leukemia MieloGlobeNewswire
- SELLAS 라이프사이언스, 면역항암 백신 갈린페피무트-S(GPS)의 급성 골수성 백혈병 환자 대상 전체생존기간 개선 효과 입증한 핵심 임상 3상 REGAL 시험에서 긍정적 결과 발표GlobeNewswire
- セラス・ライフ・サイエンシズ、リーガルと呼ばれる重要な第3相試験の良好なデータを発表、がん免疫療法ワクチンであるガリンペピムト-S (GPS) が、急性骨髄性白血病患者の全生存期間で統計学的に有意かつ臨床的に意義のある改善を示すGlobeNewswire
SELLAS Life Sciences Group peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited ADR | 8.37 | -3.90% | $2.84B | vs SLS |
| DYNDyne Therapeutics Inc. | 15.50 | -3.31% | $2.90B | vs SLS |
| ZLABZai Lab Limited ADR | 21.03 | -4.06% | $2.63B | vs SLS |
| ACADACADIA Pharmaceuticals Inc. | 17.11 | -2.73% | $2.96B | vs SLS |
| LEGNLegend Biotech Corporation ADR | 15.25 | -5.28% | $2.96B | vs SLS |
| XNCRXencor Inc. | 33.26 | -2.21% | $2.50B | vs SLS |
| BHCBausch Health Companies Inc. | 8.22 | -3.97% | $3.08B | vs SLS |
| IDYAIDEAYA Biosciences Inc. | 25.56 | -2.33% | $2.47B | vs SLS |
Indexes, lists and sector
SELLAS Life Sciences Group stock FAQ
What is SELLAS Life Sciences Group's stock price today?
SLS last traded at $13.66 as of Nov 20, 4:00 PM EST, down 8.08% on the day. Prices are delayed at least 15 minutes.
Does SELLAS Life Sciences Group pay a dividend?
No. SELLAS Life Sciences Group does not currently pay a regular cash dividend.
Who is SELLAS Life Sciences Group's CEO?
Dr. Angelos M. Stergiou M.D., ScD h.c. is the chief executive officer of SELLAS Life Sciences Group Inc., which has about 13 employees.
Has SLS ever split its stock?
Yes. The most recent SLS stock split was a 1-for-50 split on Nov 8, 2019, one of 3 splits on record.
What is the SLS 52-week high?
The 52-week high for SLS is $24.89 and the 52-week low is $1.39. The stock is currently 45.1% below its high.